李氏大药厂2023年年报

2023ANNUAL REPORT(incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司)(Stock Code 股份代號:950)*For identification purpose only 僅供識別年 報 CONTENTS目 錄Corporate Information2公司資料Corporate Profile4公司簡介Financial Highlights7財務概要Five-Year Financial Summary9五年財務摘要Chairman’s Statement10主席報告Management Discussion and Analysis12管理層討論及分析Directors and Key Personnel Profiles24董事及主要人員履歷Report of the Directors32董事會報告Corporate Governance Report56企業管治報告Independent Auditor’s Report68獨立核數師報告Consolidated Statement of Profit or Loss77綜合損益表Consolidated Statement of Profit or Loss and Other Comprehensive Income78綜合損益及其他全面收益表Consolidated Statement of Financial Position79綜合財務狀況表Consolidated Statement of Changes in Equity81綜合權益變動表Consolidated Statement of Cash Flows83綜合現金流量表Notes to the Consolidated Financial Statements85綜合財務報表附註Definition226釋義 Lee’s Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司2Corporate Information公司資料BOARD OF DIRECTORSExecutive DirectorsMs. Lee Siu Fong (Chairman)Ms. Leelalertsuphakun Wanee (Managing Director)Non-executive DirectorsDr. Li XiaoyiMr. James Charles GaleIndependent Non-executive DirectorsDr. Chan Yau Ching, BobMs. Cheang Yee Wah, Eva (appointed with effect from 17 May 2023)Mr. Lam Yat Cheong (resigned with effect from 17 May 2023)Dr. Tsim Wah Keung, KarlCOMPANY SECRETARYMr. Chow Yiu MingAUDIT COMMITTEEDr. Chan Yau Ching, Bob (Chairman)Ms. Cheang Yee Wah, Eva (appointed with effect from 17 May 2023)Mr. Lam Yat Cheong (resigned with effect from 17 May 2023)Dr. Tsim Wah Keung, KarlREMUNERATION COMMITTEEDr. Tsim Wah Keung, Karl (Chairman)Ms. Leelalertsuphakun WaneeDr. Chan Yau Ching, BobNOMINATION COMMITTEEMs. Lee Siu Fong (Chairman)Dr. Chan Yau Ching, BobDr. Tsim Wah Keung, KarlMANAGEMENT COMMITTEEMs. Leelalertsuphakun Wanee (Chairman)Ms. Lee Siu Fong董事會執行董事李小芳女士（主席）李燁妮女士（董事總經理）非執行董事李小羿博士James Charles Gale先生獨立非執行董事陳友正博士蔣綺華女士 （任命自二零二三年五月十七日起生效）林日昌先生 （辭任自二零二三年五月十七日起生效）詹華強博士公司秘書鄒耀明先生審核委員會陳友正博士（主席）蔣綺華女士 （任命自二零二三年五月十七日起生效）林日昌先生 （辭任自二零二三年五月十七日起生效）詹華強博士薪酬委員會詹華強博士（主席）李燁妮女士陳友正博士提名委員會李小芳女士（主席）陳友正博士詹華強博士管理委員會李燁妮女士（主席）李小芳女士 Annual Report 2023 年報3Corporate Information公司資料核數師天健國際會計師事務所有限公司執業會計師法律顧問金杜律師事務所（香港法律）北京市五環律師事務所（中國法律）註冊辦事處PO Box 309Ugland House, Grand CaymanKY1-1104, Cayman Islands香港營業地點香港沙田香港科學園第三期20E大樓一樓香港股份過戶登記處 香港中央證券登記有限公司香港灣仔皇后大道東183號合和中心17樓1712–1716舖授權代表李小芳女士李燁妮女士網站www.leespharm.com股份代號950AUDITORConfucius International CPA LimitedCertified Public AccountantsLEGAL ADVISERSKing & Wood Mallesons (Hong Kong law)Beijing Wuhuan Law Firm (PRC law)REGISTERED OFFICEPO Box 309Ugland House, Grand CaymanKY1-1104, Cayman IslandsPLACE OF BUSINESS IN HONG KONG1/F, Building 20E, Phase 3Hong Kong Science Park, ShatinHong KongHONG KONG SHARE REGISTRAR AND TRANSFER OFFICEComputershare Hong Kong Investor Services LimitedShops 1712–1716, 17th Floor, Hopewell Centre183 Queen’s Road East, WanchaiHong KongAUTHORISED REPRESENTATIVESMs. Lee Siu FongMs. Leelalertsuphakun WaneeWEBSITEwww.leespharm.comSTOCK CODE950 Corporate Profile公司簡介Lee’s Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司4The Company is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China.The Group is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Group has established extensive partnerships with over 20 international companies and currently markets over 25 proprietary, generic and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan.The Group focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology and obstetrics. It has more than 40 products under different development stages stemming from both internal research and development as well as from the licensing of development, commercialisation, and manufacturing rights from various United States, European and Japanese companies.The Group carries out its sales and distribution activities in Hong Kong, Macau, Taiwan and Mainland China through Hong Kong and Taiwan offices and branch offices in Chongqing, Guangzhou, Shanghai and Beijing with direct and channel sales network covering most of the provinces and cities in Mainland China, marketing both domestic self-developed and generic products and overseas licensed-in products. The Group has just established an office in Thailand with the intention of conducting sales and distribution activities within the Thai market in the near future. Zhaoke Hefei, is currently operating the manufacturing plant of the Group located in Hefei, Anhui Province of the PRC, comprising four GMP-compliant workshops for the production of topical gel, lyophilised powder for injection, small volume parenteral solu